In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
Cannabidiol has low affinity for the cannabinoid CB1 and CB2 receptors, although it can act as an antagonist of CB1/CB2 agonists despite this low affinity. Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It also may act as an inverse agonist of GPR3, GPR6, and GPR12. CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD may involve PPARγ agonism and intracellular calcium release.
Cannabis – A type of flowering plant that includes three distinct variations: Cannabis ruderalis, Cannabis indica, and Cannabis sativa. Cannabis has a wide range of industrial and medical applications. It has been used since antiquity for its sturdy fiber, for oils, and for medicinal purposes. However, it has also been used as a recreational drug, a fact that renders the cultivation of cannabis strictly regulated because of some variations including high concentrations of THC.
However, when cannabinoids are taken externally, it’s difficult to distinguish between the clinically desirable effects and the therapeutically undesirable effects of various phytocannabinoids. This is because cannabinoid receptors send a variety of signals that often interconnect to coordinate the body’s functions, so it’s hard to tell them apart.
A disclaimer here: I am not a professional in this field. The symptoms I describe below and attribute to either to under or over dose of nicotine are information I have assembled by reading web sites and published studies; my advice is based only on that. I can not promise that they are absolute indications. Above all in your process of switching to vaping, listen to your body. If you can work out what it is telling you then that’s the best advice of all. vaping